Seres Therapeutics, Inc. (MCRB) SEC Filings — 2024

Filings

• Seres Therapeutics 8-K: Delisting Notice & Financials — 8-K · Nov 13, 2024
• Seres Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 13, 2024
• Nestlé Amends Seres Therapeutics Stake Filing — SC 13D/A · Oct 2, 2024
• Seres Therapeutics Terminates Nestle Health Science Agreement — 8-K · Oct 1, 2024
• Seres Therapeutics Files 8-K Report — 8-K · Sep 26, 2024
• Nestlé to Acquire Seres Therapeutics for $1.9 Billion — 8-K · Sep 12, 2024
• Seres Therapeutics Files 8-K with Financial Updates — 8-K · Aug 15, 2024
• Seres Therapeutics Files 8-K on Financials — 8-K · Aug 13, 2024
• Seres Therapeutics Proxy Filing: Earnings Call Solicitation — DEFA14A · Aug 13, 2024
• Seres Therapeutics Q2 2024 Update: R&D Expenses and Nestle Deal — 10-Q · Aug 13, 2024
• Seres Therapeutics Files Proxy Statement — DEFA14A · Aug 7, 2024
• Seres Therapeutics Files 8-K Report — 8-K · Aug 6, 2024
• Seres Therapeutics Files 8-K on Financials — 8-K · May 8, 2024
• Seres Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024
• Seres Therapeutics Reports Financial Obligation Event — 8-K · May 7, 2024
• Seres Therapeutics Faces Delisting Concerns — 8-K · Apr 23, 2024
• Seres Therapeutics Files 8-K on Fiscal Year Change — 8-K · Apr 8, 2024
• Seres Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Apr 5, 2024
• Seres Therapeutics Files 8-K on Financials — 8-K · Mar 5, 2024
• Seres Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 5, 2024
• Seres Therapeutics Reports Officer Changes and Disclosure — 8-K · Feb 26, 2024
• Janus Henderson Amends Seres Therapeutics Stake — SC 13G/A · Feb 12, 2024
• FMR LLC & Abigail Johnson Trim Seres Therapeutics Stake to 14.999% — SC 13G/A · Feb 9, 2024
• Seres Therapeutics Updates Principal Executive Offices — 8-K · Jan 30, 2024
• BlackRock Discloses Passive 13G Stake in Seres Therapeutics — SC 13G · Jan 29, 2024
• Seres Therapeutics Files 8-K on Financial Condition Update — 8-K · Jan 10, 2024
• Seres Therapeutics Updates Principal Executive Office Address — 8-K · Jan 9, 2024
• Seres Therapeutics Enacts 1-for-10 Reverse Stock Split — 8-K · Jan 2, 2024